ABUS Fail-to-Deliver
Arbutus Biopharma Corp (ABUS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $904.7M, listed on NASDAQ, employing roughly 19 people, carrying a beta of 0.63 to the broader market. Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Led by Lindsay Androski, public since 2007-07-26.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
- Latest Date
- 2026-06-12
- Latest FTD Quantity
- 68
- Latest Price
- $4.29
- 30-Day Avg FTD
- 20.2K
- 30-Day Total FTD
- 607.3K
Showing 30 days of SEC fail-to-deliver data for Arbutus Biopharma Corp.
Learn how fails-to-deliver is reported and how to read the data →
Frequently asked ABUS fail to deliver questions
- What is the latest ABUS fail-to-deliver count?
- As of Jun 12, 2026, Arbutus Biopharma Corp (ABUS) fail-to-deliver quantity is 68 shares, with a 30-day average of 20.2K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
- What is the FTD aggregate net balance?
- FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
- How do ABUS FTDs affect options pricing?
- Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.